Latest Breaking News On - Matt crenson - Page 1 : comparemela.com

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomMatt crensonIan karpAlina liJohn leonardCompany progressEuropean commissionHealth care conferenceEuropean medicines agencyRegeneron pharmaceuticals incCompany at the marketExchange commissionCorporate communicationsRecode therapeutics incVivo program updates

Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis

Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomSan franciscoUnited statesShehnaaz sulimanErica jeffersonIan karpTara cooperAlina liMatt crensonJohn leonardCorporate communicationsGrace groupIntellia therapeutics incCorporate affairsRecode therapeutics incExchange commission

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in

Data reinforce the potential of NTLA-2002 to eliminate angioedema attacks in people living with hereditary angioedema (HAE) after a single doseA single dose of NTLA-2002 led to 95% mean reduction

United kingdomIan karpAlina liMatt crensonJohn leonardDrug administrationRegulatory agencyEuropean medicines agencyEuropean commissionIntellia therapeutics incCorporate communicationsClinical programEuropean academy of allergyClinical immunology hybrid congressExchange commissionNew england journal

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomMatt crensonIan karpJohn leonardAlina liEuropean medicines agencyEuropean commissionExchange commissionClinical immunology hybrid congressCorporate communicationsRegulatory agencyIntellia therapeutics incDrug administrationEuropean academy of allergyClinical programTherapeutics announces publication

Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

FDA cleared NTLA-2001 IND application for first in vivo CRISPR candidate to enter late-stage clinical development; on track to initiate the MAGNIT.

United kingdomCity ofIan karpJohn leonardAlina liMatt crensonCorporate communicationsIntellia therapeutics incExchange commissionRegeneron pharmaceuticals incVivo program updatesCompany at the marketDrug administrationEuropean medicines agencyClinical trial applicationIntellia president